Skip to main content
. 2020 Jun 11;22(9):1478–1488. doi: 10.1038/s41436-020-0840-3

Fig. 2. Solved rate by country of origin.

Fig. 2

The MYO-SEQ solved rate (in dark gray) was higher in countries such as Egypt and Turkey where the infrastructure for genetic testing for prescreening is not as widely available, and lower in Western European countries where genetic prescreening of common limb-girdle muscular dystrophy (LGMD) genes is routinely performed. Calculated for referring centers submitting more than 20 samples.